K. Zarogoulidis (Thessaloniki, Greece), S. G. Spiro (London, United Kingdom)
Is the current staging system realistic for SCLC?
K. P. Zarogoulidis, N. E. Galanis, B. Georgoulias, A. Xafenias, P. Panousis, E. Kalaitzidou, C. Kourousis, N. Androulakis, T. N. Kontakiotis (Thessaloniki, Heraclion, Greece)
|  |
Gemcitabine, ifosfamide and paclitaxel in patients with untreated advanced/metastatic nonsmall cell lung cancer (NSCLC) A phase II study
A. Bianco, F. V. Piantedosi, V. Pontillo, C. Crispino, G. Giuliarini, M. Hengeller, G. D'Addio, S. D'Agostino, S. A. Marsico, A. Lamberti (Naples, Italy)
| |
Economic evaluation of gemcitabine plus cisplatin (GD) versus vinorelbine plus cisplatin plus Ifosfamide (NIP) in patients with locally advanced or metastatic non-small-cell lung cancer
M. Borges, M. Gouveia, E. Teixeira, R. Sottomayor, A. Almeida (Lisbon, Portugal)
| |
Gefitinib (‘Iressa’, ZD1839) improves disease-related symptoms in NSCLC
| |
Management of adenoid cystic carcinoma of the trachea
P. K. Yablonsky, I. V. Vasiliev, B. B. Shafirovsky, V. F. Mous, A. R. Kozak (St Petersburg, Russia)
| |
Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma?
S. Metintas, M. Metintas, G. Ak, S. Erginel, I. Ucgun, F. Alatas (Eskisehir, Turkey)
| |
Bronchoalveolar lavage in patients with acute lung toxicity after chemo-radiotherapy for lung cancer
P. Berzinec, N. Iliev, H. Baratova, J. Galikova (Nitra, Slovakia)
| |
Phase II study of cisplatin-vinorelbine sequenced by gemcitabine-vinorelbine in patients with unresectable non-small-cell lung cancer (NSCLC): preliminary results
M. Klimathianaki, F. Vlastos, G. Patlakas, E. Argiana, G. Maltezakis, M. Froudarakis, D. Bouros, A. Rasidakis, N. M. Siafakas (Athens, Greece)
| |
A phase I trial of combined carboplatin and topotecan as 2nd line treatment in patients (pts) with nonsmall cell lung cancer (NSCLC)
G. S. Dionellis, I. Danos, N. Georgatou, E. Psaras, A. G. Charpidou, Dimakou, K. N. Syrigos (Athens, Greece)
| |
Docetaxel (DOC) and gemcitabine (GEM) consist a safe and effective combination in the management of non-small cell lung cancer (NSCLC)
D. S. Dionellis, I. Danos, F. Skotti, A. G. Charpidou, F. Alevizaki, K. N. Syrigos (Athens, Greece)
| |
Satisfractory therapeutic effects of EGFR-TK treatment of a malignant mesothelioma of the pleura: a case report
J. S. Stanic, Z. S. Eri, I. I. Klem, S. J. Knezevic-Usaj, M. M. Antonic, A. M. Andjelkovic (Sremska Kamenica, Yugoslavia)
| |
Correlation of quality of life parameters with parameters of health state in patients with nonsmall cell lung cancer treated by chemotherapy
S. Rancic, M. Rancic, M. Cekic, L. Ristic, D. J. Zivkovic, I. Stankovic, D. Djordjevic, T. Pejcic (Nis, Yugoslavia)
| |
A multicenter phase II study of carboplatin/vinorelbine in advanced non-small cell lung cancer (NSCLC) in elderly patients (GFPC 9902)
H. LeCaer, J. Y. Delhoume, P. A. Thomas, H. Berard (Draguignan, Perigueux, Marseille, Toulon, France)
| |
Front-line weekly gemcitabine (G) for unfit or elderly patients with non-small cell lung cancer (NSCLC)
G. Buccheri, D. Ferrigno (Cuneo, Italy)
| |
Survival and postoperative complication after neoadjuvant therapy in resectable stage IIIA-N2 non-small cell lung cancer: a balancing exercise
F. Barlesi, C. Doddoli, B. Chetaille, C. Gimenez, R. Giudicelli, P. Fuentes, J. P. Kleisbauer, P. Thomas (Marseille, France)
| |
Combined radiotherapy for nonsmall cell lung cancer
S. S. Vucicevic, K. M. Dabic-Stankovic, N. P. Jovanovic, E. S. Sudzic (Belgrade, Yugoslavia)
| |
The approach to the surgical management of cancer in four European countries (Belgium, Greece, Switzerland, United Kingdom)
C. K. Connolly, P. E. Van Schil, O. Braendli, R. Milroy, R. Prescott (Richmond, United Kingdom)
| |
Preliminary results of a multicenter randomized phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non small cell lung cancer (NSCLC)
A. Rapti, E. Tsaroucha, S. Tsagouli, M. Masmanidi, O. Chioni, V. Panagoulias, O. Anagnostopoulou, V. Georgoulias (Athens, Heraklion, Greece)
| |
Docetaxel as second-line chemotherapy (CT) in advanced non small cell lung cancer(NSCLC) patients (pts): does it really work?
P. S. Barradas, A. S. Oliveira, A. M. Costa, A. M. Figueiredo, F. J. Barata, A. P. Alves, M. M. Cristovao, M. J. S. Melo (Lisboa, Coimbra, Portugal)
| |
Safety and tolerability of gefitinib in advanced NSCLC: overview of clinical experience
B. Forsythe, K. Faulkner (Macclesfield, United Kingdom)
| |